Market research
600196.SHG Shanghai Fosun Pharmaceutical (Group) Co., Ltd
SHG CNY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 63B
- P/E ratio
- 17.98
- Analyst target
- 34.464
- Dividend yield
- 1.6%
- Beta
- 0.44
Profile
Company facts
- Exchange
- SHG
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CNE000000X38
- Market cap
- 63B
- P/E ratio
- 17.98
- Analyst target
- 34.464
- Dividend yield
- 1.6%
- Beta
- 0.44
About
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 600196.SHG discussion.
5 years, 5 months ago
Shanghai Fosun Pharmaceutical (Group) Co., Ltd is currently in a long term uptrend where the price is trading 21.5% above its 200 day moving average.
From a valuation standpoint, the stock is 64.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.4.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd's total revenue rose by 11.5% to $8B since the same quarter in the previous year.
Its net income has dropped by 5.9% to $1B since the same quarter in the previous year.
Finally, its free cash flow fell by 411.9% to $-1B since the same quarter in the previous year.
Based on the above factors, Shanghai Fosun Pharmaceutical (Group) Co., Ltd gets an overall score of 3/5.